1.          Introduction

1.1         Scope of the Study

1.2         The Insight Partners Research Report Guidance

1.3         Market Segmentation

1.3.1        SAM Insulin Market – By Type

1.3.2        SAM Insulin Market – By Country

2.           SAM Insulin Market – Key Takeaways

3.        Research Methodology

3.1         Coverage

3.2         Secondary Research

3.3         Primary Research

4.           SAM Insulin Market – Market Landscape

4.1         Overview

4.2         SAM PEST Analysis

4.2.1        Expert Opinion

5.           SAM Insulin Market– Key Market Dynamics

5.1         Market Drivers

5.1.1        Increase in Incidence of Diabetes

5.1.2        Rapid Technological Developments in Insulin Delivery Devices by Major Players

5.2         Market Restraints

5.2.1        Risks Associated with Insulin Delivery Devices

5.3         Market Opportunities

5.3.1        Insufficient Competition from Biosimilars

5.4         Future Trends

5.4.1        Regeneration of Diabetic Pancreas with Advanced Transplants

5.5         Impact Analysis

6.           Insulin Market– SAM Analysis

6.1         SAM Insulin Market Revenue Forecast and Analysis

7.           SAM Insulin Market Analysis – By Type

7.1         Overview

7.2         SAM Insulin Market Revenue Share, by Type (2021 and 2028)

7.3         Long Acting Insulin

7.3.1        Overview

7.3.2        Long Acting Insulin: Insulin Market – Revenue and Forecast to 2028 (US$ Million)

7.3.2.1          Levemir

7.3.2.1.1          Overview

7.3.2.1.2          Levemir: Insulin Market – Revenue and Forecast to 2028 (US$ Million)

7.3.2.2          Lantus

7.3.2.2.1          Overview

7.3.2.2.2          Lantus: Insulin Market – Revenue and Forecast to 2028 (US$ Million)

7.3.2.3          Basaglar

7.3.2.3.1          Overview

7.3.2.3.2          Basaglar: Insulin Market – Revenue and Forecast to 2028 (US$ Million)

7.3.2.4          Tresiba

7.3.2.4.1          Overview

7.3.2.4.2          Tresiba: Insulin Market – Revenue and Forecast to 2028 (US$ Million)

7.4         Rapid Acting Insulins

7.4.1        Overview

7.4.2        Rapid Acting Insulins: Insulin Market – Revenue and Forecast to 2028 (US$ Million)

7.4.2.1          Novolog

7.4.2.1.1          Overview

7.4.2.1.2          Novolog: Insulin Market – Revenue and Forecast to 2028 (US$ Million)

7.4.2.2          Humalog

7.4.2.2.1          Overview

7.4.2.2.2          Humalog: Insulin Market – Revenue and Forecast to 2028 (US$ Million)

7.4.2.3          Admelog

7.4.2.3.1          Overview

7.4.2.3.2          Admelog: Insulin Market – Revenue and Forecast to 2028 (US$ Million)

7.4.2.4          Others

7.4.2.4.1          Overview

7.4.2.4.2          Others: Insulin Market – Revenue and Forecast to 2028 (US$ Million)

7.5         Short Acting Insulins and Traditional Human Insulins

7.5.1        Overview

7.5.2        Short Acting Insulins and Traditional Human Insulins: Insulin Market – Revenue and Forecast to 2028 (US$ Million)

7.5.2.1          Novolin R

7.5.2.1.1          Overview

7.5.2.1.2          Novolin R: Insulin Market – Revenue and Forecast to 2028 (US$ Million)

7.5.2.2          Humulin R

7.5.2.2.1          Overview

7.5.2.2.2          Humulin R: Insulin Market – Revenue and Forecast to 2028 (US$ Million)

7.5.2.3          Insuman

7.5.2.3.1          Overview

7.5.2.3.2          Insuman: Insulin Market – Revenue and Forecast to 2028 (US$ Million)

7.5.2.4          Others

7.5.2.4.1          Overview

7.5.2.4.2          Others: Insulin Market – Revenue and Forecast to 2028 (US$ Million)

7.6         Concentrated Insulins and Combination Insulins

7.6.1        Overview

7.6.2        Concentrated Insulins and Combination Insulins: Insulin Market – Revenue and Forecast to 2028 (US$ Million)

7.6.2.1          NovoMix

7.6.2.1.1          Overview

7.6.2.1.2          NovoMix: Insulin Market – Revenue and Forecast to 2028 (US$ Million)

7.6.2.2          Ryzodeg

7.6.2.2.1          Overview

7.6.2.2.2          Ryzodeg: Insulin Market – Revenue and Forecast to 2028 (US$ Million)

7.6.2.3          Xultophy

7.6.2.3.1          Overview

7.6.2.3.2          Xultophy: Insulin Market – Revenue and Forecast to 2028 (US$ Million)

7.6.2.4          Soliqua/Suliqua

7.6.2.4.1          Overview

7.6.2.4.2          Soliqua/Suliqua: Insulin Market – Revenue and Forecast to 2028 (US$ Million)

7.7         Biosimilar Insulins

7.7.1        Overview

7.7.2        Biosimilar Insulins: Insulin Market – Revenue and Forecast to 2028 (US$ Million)

7.7.2.1          Insulin Glargine

7.7.2.1.1          Overview

7.7.2.1.2          Insulin Glargine: Insulin Market – Revenue and Forecast to 2028 (US$ Million)

7.7.2.2          Human Insulin

7.7.2.2.1          Overview

7.7.2.2.2          Human Insulin: Insulin Market – Revenue and Forecast to 2028 (US$ Million)

7.8         Glucagon-like peptide-1 (GLP-1)

7.8.1        Overview

7.8.2        Glucagon-like peptide-1 (GLP-1): Insulin Market – Revenue and Forecast to 2028 (US$ Million)

7.9         Pens and Needles

7.9.1        Overview

7.9.2        Pens and Needles: Insulin Market – Revenue and Forecast to 2028 (US$ Million)

7.10      Others

7.10.1     Overview

7.10.2     Others: Insulin Market – Revenue and Forecast to 2028 (US$ Million)

8.           SAM Insulin Market – Country Analysis

8.1         Overview

8.1.1        SAM Insulin Market Revenue and Forecast to 2028, by Country (%)

8.1.1.1          Brazil: Insulin Market – Revenue and Forecast to 2028 (USD Million)

8.1.1.1.1          Brazil: Insulin Market – Revenue and Forecast to 2028 (USD Million)

8.1.1.1.2          Brazil: Insulin Market, By Type, 2019–2028 (US$ Million)

8.1.1.1.2.1       Brazil: Insulin Market, By Long Acting Insulin, 2019–2028 (US$ Million)

8.1.1.1.2.2       Brazil: Insulin Market, By Rapid Acting Insulin, 2019–2028 (US$ Million)

8.1.1.1.2.3       Brazil: Insulin Market, By Short-acting Insulins and Traditional Human Insulins, 2019–2028 (US$ Million)

8.1.1.1.2.4       Brazil: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019–2028 (US$ Million)

8.1.1.1.2.5       Brazil: Insulin Market, By Biosimilar Insulins, 2019–2028 (US$ Million)

8.1.1.2          Argentina: Insulin Market – Revenue and Forecast to 2028 (USD Million)

8.1.1.2.1          Argentina: Insulin Market – Revenue and Forecast to 2028 (USD Million)

8.1.1.2.2          Argentina: Insulin Market, By Type, 2019–2028 (US$ Million)

8.1.1.2.2.1       Argentina: Insulin Market, By Long Acting Insulin, 2019–2028 (US$ Million)

8.1.1.2.2.2       Argentina: Insulin Market, By Rapid Acting Insulin, 2019–2028 (US$ Million)

8.1.1.2.2.3       Argentina: Insulin Market, By Short-acting Insulins and Traditional Human Insulins, 2019–2028 (US$ Million)

8.1.1.2.2.4       Argentina: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019–2028 (US$ Million)

8.1.1.2.2.5       Argentina: Insulin Market, By Biosimilar Insulins, 2019–2028 (US$ Million)

8.1.1.3          Rest of SAM: Insulin Market – Revenue and Forecast to 2028 (USD Million)

8.1.1.3.1          Rest of SAM: Insulin Market – Revenue and Forecast to 2028 (USD Million)

8.1.1.3.2          Rest of SAM: Insulin Market, By Type, 2019–2028 (US$ Million)

8.1.1.3.2.1       Rest of SAM: Insulin Market, By Long Acting Insulin, 2019–2028 (US$ Million)

8.1.1.3.2.2       Rest of SAM: Insulin Market, By Rapid Acting Insulin, 2019–2028 (US$ Million)

8.1.1.3.2.3       Rest of SAM: Insulin Market, By Short acting Insulins and Traditional Human Insulins, 2019–2028 (US$ Million)

8.1.1.3.2.4       Rest of SAM: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019–2028 (US$ Million)

8.1.1.3.2.5       Rest of SAM: Insulin Market, By Biosimilar Insulins, 2019–2028 (US$ Million)

9.           SAM Insulin Market–Industry Landscape

9.1         Overview

9.2         Organic Developments

9.2.1        Overview

9.3         Inorganic Developments

9.3.1        Overview

10.        Company Profile

10.1      Eli Lilly and Company

10.1.1     Key Facts

10.1.2     Business Description

10.1.3     Products and Services

10.1.4     Financial Overview

10.1.5     SWOT Analysis

10.1.6     Key Developments

10.2      Novo Nordisk A/S

10.2.1     Key Facts

10.2.2     Business Description

10.2.3     Products and Services

10.2.4     Financial Overview

10.2.5     SWOT Analysis

10.2.6     Key Developments

10.3      Biocon

10.3.1     Key Facts

10.3.2     Business Description

10.3.3     Products and Services

10.3.4     Financial Overview

10.3.5     SWOT Analysis

10.3.6     Key Developments

10.4      Wockhardt

10.4.1     Key Facts

10.4.2     Business Description

10.4.3     Products and Services

10.4.4     Financial Overview

10.4.5     SWOT Analysis

10.4.6     Key Developments

10.5      GlaxoSmithKline plc.

10.5.1     Key Facts

10.5.2     Business Description

10.5.3     Products and Services

10.5.4     Financial Overview

10.5.5     SWOT Analysis

10.5.6     Key Developments

10.6      Sanofi

10.6.1     Key Facts

10.6.2     Business Description

10.6.3     Products and Services

10.6.4     Financial Overview

10.6.5     SWOT Analysis

10.6.6     Key Developments

10.7      Pfizer Inc.

10.7.1     Key Facts

10.7.2     Business Description

10.7.3     Products and Services

10.7.4     Financial Overview

10.7.5     SWOT Analysis

10.7.6     Key Developments

10.8      Merck & Co., Inc.

10.8.1     Key Facts

10.8.2     Business Description

10.8.3     Products and Services

10.8.4     Financial Overview

10.8.5     SWOT Analysis

10.8.6     Key Developments

10.9      Tonghua Dongbao Pharmaceutical Co., Ltd.

10.9.1     Key Facts

10.9.2     Business Description

10.9.3     Products and Services

10.9.4     Financial Overview

10.9.5     SWOT Analysis

10.9.6     Key Developments

11.        Appendix

11.1      About The Insight Partners

11.2      Glossary of Terms

LIST OF TABLES

Table 1.             SAM Insulin Market, Revenue and Forecast, 2019–2028 (US$ Million)

Table 2.             Brazil: Insulin Market, By Type – Revenue and Forecast to 2028 (US$ Million)

Table 3.             Brazil: Insulin Market, By Long Acting Insulin – Revenue and forecast to 2028 (US$ Million)

Table 4.             Brazil: Insulin Market, By Rapid Acting Insulin - Revenue and Forecast to 2028 (US$ Million)

Table 5.             Brazil: Insulin Market, By Short-acting Insulins and Traditional Human Insulins - Revenue and Forecast to 2028 (US$ Million)

Table 6.             Brazil: Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)

Table 7.             Brazil: Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)

Table 8.             Argentina: Insulin Market, By Type – Revenue and Forecast to 2028 (US$ Million)

Table 9.             Argentina: Insulin Market, By Long Acting Insulin – Revenue and forecast to 2028 (US$ Million)

Table 10.          Argentina: Insulin Market, By Rapid Acting Insulin - Revenue and Forecast to 2028 (US$ Million)

Table 11.          Argentina: Insulin Market, By Short-acting Insulins and Traditional Human Insulins - Revenue and Forecast to 2028 (US$ Million)

Table 12.          Argentina: Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)

Table 13.          Argentina: Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)

Table 14.          Rest of SAM: Insulin Market, By Type – Revenue and Forecast to 2028 (US$ Million)

Table 15.          Rest of SAM: Insulin Market, By Long Acting Insulin – Revenue and forecast to 2028 (US$ Million)

Table 16.          Rest of SAM: Insulin Market, By Rapid Acting Insulin - Revenue and Forecast to 2028 (US$ Million)

Table 17.          Rest of SAM: Insulin Market, By Short acting Insulins and Traditional Human Insulins - Revenue and Forecast to 2028 (US$ Million)

Table 18.          Rest of SAM: Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)

Table 19.          Rest of SAM: Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)

Table 20.          Organic Developments in the Insulin Market

Table 21.          Inorganic Developments in the Insulin Market

Table 22.          Glossary of Terms, SAM Insulin Market

LIST OF FIGURES

Figure 1.           SAM Insulin Market Segmentation

Figure 2.           SAM Insulin Market Segmentation, By Country

Figure 3.           SAM Insulin Market Overview

Figure 4.           The Long Acting Insulin Segment Held Largest Share of Type in the Insulin Market

Figure 5.           Rest of SAM Is Expected to Show Remarkable Growth During the Forecast Period

Figure 7.           South America PEST Analysis

Figure 8.           Expert Opinion

Figure 9.           SAM Insulin Market Impact Analysis of Drivers and Restraints

Figure 10.        SAM Insulin Market– Revenue Forecast and Analysis

Figure 11.        SAM Insulin Market Revenue Share, by Type (2021 and 2028)

Figure 12.        SAM Long Acting Insulin: Insulin Market – Revenue and Forecast to 2028 (US$ Million)

Figure 13.        SAM Levemir: Insulin Market – Revenue and Forecast to 2028 (US$ Million)

Figure 14.        SAM Lantus: Insulin Market – Revenue and Forecast to 2028 (US$ Million)

Figure 15.        SAM Basaglar: Insulin Market – Revenue and Forecast to 2028 (US$ Million)

Figure 16.        SAM Tresiba: Insulin Market – Revenue and Forecast to 2028 (US$ Million)

Figure 17.        SAM Rapid Acting Insulins: Insulin Market – Revenue and Forecast to 2028 (US$ Million)

Figure 18.        SAM Novolog: Insulin Market – Revenue and Forecast to 2028 (US$ Million)

Figure 19.        SAM Humalog: Insulin Market – Revenue and Forecast to 2028 (US$ Million)

Figure 20.        SAM Admelog: Insulin Market – Revenue and Forecast to 2028 (US$ Million)

Figure 21.        SAM Others: Insulin Market – Revenue and Forecast to 2028 (US$ Million)

Figure 22.        SAM Short Acting Insulins and Traditional Human Insulins: Insulin Market – Revenue and Forecast to 2028 (US$ Million)

Figure 23.        SAM Novolin R: Insulin Market – Revenue and Forecast to 2028 (US$ Million)

Figure 24.        SAM Humulin R: Insulin Market – Revenue and Forecast to 2028 (US$ Million)

Figure 25.        SAM Insuman: Insulin Market – Revenue and Forecast to 2028 (US$ Million)

Figure 26.        SAM Others: Insulin Market – Revenue and Forecast to 2028 (US$ Million)

Figure 27.        SAM Concentrated Insulins and Combination Insulins: Insulin Market – Revenue and Forecast to 2028 (US$ Million)

Figure 28.        SAM NovoMix: Insulin Market – Revenue and Forecast to 2028 (US$ Million)

Figure 29.        SAM Ryzodeg: Insulin Market – Revenue and Forecast to 2028 (US$ Million)

Figure 30.        SAM Xultophy: Insulin Market – Revenue and Forecast to 2028 (US$ Million)

Figure 31.        SAM Soliqua/Suliqua: Insulin Market – Revenue and Forecast to 2028 (US$ Million)

Figure 32.        SAM Biosimilar Insulins: Insulin Market – Revenue and Forecast to 2028 (US$ Million)

Figure 33.        SAM Insulin Glargine: Insulin Market – Revenue and Forecast to 2028 (US$ Million)

Figure 34.        SAM Human Insulin: Insulin Market – Revenue and Forecast to 2028 (US$ Million)

Figure 35.        SAM Glucagon-like peptide-1 (GLP-1): Insulin Market – Revenue and Forecast to 2028 (US$ Million)

Figure 36.        SAM Pens and Needles: Insulin Market – Revenue and Forecast to 2028 (US$ Million)

Figure 37.        SAM Others: Insulin Market – Revenue and Forecast to 2028 (US$ Million)

Figure 38.        SAM Insulin Market Revenue Overview, By Country (2021) (US$ Mn)

Figure 39.        SAM Insulin Market Revenue and Forecast to 2028, by Country (%)

Figure 40.        Brazil: Insulin Market – Revenue and Forecast to 2028 (USD Million)

Figure 41.        Argentina: Insulin Market – Revenue and Forecast to 2028 (USD Million)

Figure 42.        Rest of SAM: Insulin Market – Revenue and Forecast to 2028 (USD Million)